Status:
ACTIVE_NOT_RECRUITING
Post COVID-19 Syndrome and the Gut-lung Axis
Lead Sponsor:
Medical University of Graz
Collaborating Sponsors:
CBmed Ges.m.b.H.
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The outbreak of the novel coronavirus (SARS-CoV-2)-infected disease (COVID-19) began in December 2019, spread throughout China in early 2020 and developed as a pandemic thereafter. Based on current k...
Eligibility Criteria
Inclusion
- 18 years or older
- Covid-19 infection with severe disease defined within the last 12 months (defined as one or more of the following: hospitalization, need for oxygen supply, need for intensive care treatment, need for specific treatment of Covid disease, antibiotic treatment)
- Subjective presence of residual symptoms of Covid disease OR no residual symptoms of Covid disease (Controls)
- Informed consent
Exclusion
- Continuous probiotic treatment in the last 4 weeks before inclusion
- Pre-existing lung diseases
Key Trial Info
Start Date :
June 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04813718
Start Date
June 2 2021
End Date
December 1 2025
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Graz
Graz, Austria